Profound Medical Corp. (PROF)

NASDAQ: PROF · IEX Real-Time Price · USD
8.32
-0.01 (-0.12%)
Feb 27, 2024, 3:59 PM EST - Market closed
-0.12%
Market Cap 205.29M
Revenue (ttm) 4.78M
Net Income (ttm) -12.70M
Shares Out 24.42M
EPS (ttm) -1.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 70,836
Open 8.18
Previous Close 8.33
Day's Range 8.18 - 8.63
52-Week Range 7.11 - 15.49
Beta 0.84
Analysts Buy
Price Target 12.94 (+55.53%)
Earnings Date Mar 7, 2024

About PROF

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Dr. Arun Swarup Menawat MBA, Ph.D.
Employees 131
Stock Exchange NASDAQ
Ticker Symbol PROF
Full Company Profile

Financial Performance

In 2022, PROF's revenue was 6.68 million, a decrease of -2.79% compared to the previous year's 6.87 million. Losses were -16.58 million, -45.68% less than in 2021.

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for PROF stock is "Buy." The 12-month stock price forecast is $12.94, which is an increase of 55.53% from the latest price.

Price Target
$12.94
(55.53% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

20 hours ago - GlobeNewsWire

Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

12 days ago - GlobeNewsWire

Profound Medical Announces Non-Brokered Private Placement

TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce that the Company has entered into subscription agreements,...

6 weeks ago - GlobeNewsWire

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues

TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

7 weeks ago - GlobeNewsWire

Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares

TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) today announced the pricing of its previously announced underwritten public offer...

2 months ago - GlobeNewsWire

Profound Medical Announces Proposed Public Offering of Common Shares

TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) is pleased to announce the commencement of an underwritten public offering in the...

2 months ago - GlobeNewsWire

Profound Medical to Participate in the Stifel 2023 Healthcare Conference

TORONTO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

3 months ago - GlobeNewsWire

Profound Medical Announces CMS Extension of Temporary ‘Code' for TULSA to ASC Setting

TORONTO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

4 months ago - GlobeNewsWire

Profound Medical Announces Third Quarter 2023 Financial Results

TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

4 months ago - GlobeNewsWire

Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow

TORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

4 months ago - GlobeNewsWire

Profound Medical 2023 Virtual Analyst & Investor Day Agenda

TORONTO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

5 months ago - GlobeNewsWire

Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost

The first of the TULSA AI modules, Thermal Boost enables predictable, customized ablation at the prostate capsule The first of the TULSA AI modules, Thermal Boost enables predictable, customized ablat...

5 months ago - GlobeNewsWire

Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference

TORONTO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizabl...

5 months ago - GlobeNewsWire

Profound Medical Announces At-the-Market Offering of up to US$30,000,000

TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) announces that it has established an at-the-market equity program (the “ATM Pr...

6 months ago - GlobeNewsWire

Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow

TORONTO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

7 months ago - GlobeNewsWire

Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases

TORONTO, June 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

9 months ago - GlobeNewsWire

Profound Medical Announces Upcoming Investor Events

TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

9 months ago - GlobeNewsWire

Profound Medical to Participate in A.G.P.'s Virtual Healthcare Conference

TORONTO, May 18, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,...

10 months ago - GlobeNewsWire

Profound Medical Annual and Special Meeting of Shareholders Voting Results

TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of...

10 months ago - GlobeNewsWire

TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting

– Presentations reinforce the safety, efficacy and durability of the TULSA procedure, further supporting its potential as a mainstream, whole gland or focal treatment for prostate disease –

10 months ago - GlobeNewsWire

Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow

TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizabl...

11 months ago - GlobeNewsWire

Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizabl...

11 months ago - GlobeNewsWire

Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results

Company confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSA Company confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSA

1 year ago - GlobeNewsWire

Profound Medical to Present at the 43rd Annual Cowen Health Care Conference

TORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizabl...

1 year ago - GlobeNewsWire

Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow

TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable...

1 year ago - GlobeNewsWire